Literature DB >> 21968532

TDP-43 pathological changes in early onset familial and sporadic Alzheimer's disease, late onset Alzheimer's disease and Down's syndrome: association with age, hippocampal sclerosis and clinical phenotype.

Yvonne S Davidson1, Samantha Raby, Penelope G Foulds, Andrew Robinson, Jennifer C Thompson, Stephen Sikkink, Imran Yusuf, Hanan Amin, Daniel DuPlessis, Claire Troakes, Safa Al-Sarraj, Carolyn Sloan, Margaret M Esiri, Vee P Prasher, David Allsop, David Neary, Stuart M Pickering-Brown, Julie S Snowden, David M A Mann.   

Abstract

TDP-43 immunoreactive (TDP-43-ir) pathological changes were investigated in the temporal cortex and hippocampus of 11 patients with autosomal dominant familial forms of Alzheimer's disease (FAD), 169 patients with sporadic AD [85 with early onset disease (EOAD) (i.e before 65 years of age), and 84 with late onset after this age (LOAD)], 50 individuals with Down's Syndrome (DS) and 5 patients with primary hippocampal sclerosis (HS). TDP-43-ir pathological changes were present, overall, in 34/180 of AD cases. They were present in 1/11 (9%) FAD, and 9/85 (10%) EOAD patients but were significantly more common (p = 0.003) in LOAD where 24/84 (29%) patients showed such changes. There were no demographic differences, other than onset age, between AD patients with or without TDP-43-ir pathological changes. Double immunolabelling indicated that these TDP-43-ir inclusions were frequently ubiquitinated, but were only rarely AT8 (tau) immunoreactive. Only 3 elderly DS individuals and 4/5 cases of primary HS showed similar changes. Overall, 21.7% of AD cases and 6% DS cases showed hippocampal sclerosis (HS). However, only 9% FAD cases and 16% EOAD cases showed HS, but 29% LOAD cases showed HS. The proportion of EOAD cases with both TDP-43 pathology and HS tended to be greater than those in LOAD, where nearly half of all the cases with TDP-43 pathology did not show HS. The presence of TDP-43-ir changes in AD and DS may therefore be a secondary phenomenon, relating more to ageing than to AD itself. Nevertheless, a challenge to such an interpretation comes from the finding in AD of a strong relationship between TDP-43 pathology and cognitive phenotype. Patients with TDP-43 pathology were significantly more likely to present with an amnestic syndrome than those without (p < 0.0001), in keeping with pathological changes in medial temporal lobe structures. HS was also associated more commonly with an amnestic presentation (p < 0.005), but this association disappeared when TDP-43-positive cases were excluded from the analysis. TDP-43 may, after all, be integral to the pathology of AD, and to some extent determine the clinical phenotype present.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21968532     DOI: 10.1007/s00401-011-0879-y

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  72 in total

Review 1.  ABCC9/SUR2 in the brain: Implications for hippocampal sclerosis of aging and a potential therapeutic target.

Authors:  Peter T Nelson; Gregory A Jicha; Wang-Xia Wang; Eseosa Ighodaro; Sergey Artiushin; Colin G Nichols; David W Fardo
Journal:  Ageing Res Rev       Date:  2015-07-28       Impact factor: 10.895

Review 2.  The genetics and neuropathology of Alzheimer's disease.

Authors:  Gerard D Schellenberg; Thomas J Montine
Journal:  Acta Neuropathol       Date:  2012-05-23       Impact factor: 17.088

3.  TDP-43 is a key player in the clinical features associated with Alzheimer's disease.

Authors:  Keith A Josephs; Jennifer L Whitwell; Stephen D Weigand; Melissa E Murray; Nirubol Tosakulwong; Amanda M Liesinger; Leonard Petrucelli; Matthew L Senjem; David S Knopman; Bradley F Boeve; Robert J Ivnik; Glenn E Smith; Clifford R Jack; Joseph E Parisi; Ronald C Petersen; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2014-03-23       Impact factor: 17.088

4.  Detergent Insoluble Proteins and Inclusion Body-Like Structures Immunoreactive for PRKDC/DNA-PK/DNA-PKcs, FTL, NNT, and AIFM1 in the Amygdala of Cognitively Impaired Elderly Persons.

Authors:  Jozsef Gal; Jing Chen; Yuriko Katsumata; David W Fardo; Wang-Xia Wang; Sergey Artiushin; Douglas Price; Sonya Anderson; Ela Patel; Haining Zhu; Peter T Nelson
Journal:  J Neuropathol Exp Neurol       Date:  2018-01-01       Impact factor: 3.685

Review 5.  Epileptic activity in Alzheimer's disease: causes and clinical relevance.

Authors:  Keith A Vossel; Maria C Tartaglia; Haakon B Nygaard; Adam Z Zeman; Bruce L Miller
Journal:  Lancet Neurol       Date:  2017-04       Impact factor: 44.182

6.  Pathological, imaging and genetic characteristics support the existence of distinct TDP-43 types in non-FTLD brains.

Authors:  Keith A Josephs; Melissa E Murray; Nirubol Tosakulwong; Stephen D Weigand; Amanda M Serie; Ralph B Perkerson; Billie J Matchett; Clifford R Jack; David S Knopman; Ronald C Petersen; Joseph E Parisi; Leonard Petrucelli; Matthew Baker; Rosa Rademakers; Jennifer L Whitwell; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2019-01-02       Impact factor: 17.088

7.  TAR DNA-binding protein 43 pathology in Alzheimer's disease with psychosis.

Authors:  Anil Varma V Vatsavayi; Julia Kofler; Mary Ann A Demichele-Sweet; Patrick S Murray; Oscar L Lopez; Robert A Sweet
Journal:  Int Psychogeriatr       Date:  2014-03-04       Impact factor: 3.878

Review 8.  Challenges of multimorbidity of the aging brain: a critical update.

Authors:  Kurt A Jellinger; Johannes Attems
Journal:  J Neural Transm (Vienna)       Date:  2014-08-05       Impact factor: 3.575

9.  TDP-43 stage, mixed pathologies, and clinical Alzheimer's-type dementia.

Authors:  Bryan D James; Robert S Wilson; Patricia A Boyle; John Q Trojanowski; David A Bennett; Julie A Schneider
Journal:  Brain       Date:  2016-11-01       Impact factor: 13.501

10.  TDP-43 Neuropathologic Associations in the Nun Study and the Honolulu-Asia Aging Study.

Authors:  Margaret E Flanagan; Brenna Cholerton; Caitlin S Latimer; Laura S Hemmy; Steven D Edland; Kathleen S Montine; Lon R White; Thomas J Montine
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.